Table 4 Cox proportional hazard regression analysis for progression-free survival after propensity score weighting.

TACE method

5-Fu-cTACE

5-Fu-DEB-TACE

1.00

0.57(0.33–0.97)

0.041

1.00

0.59(0.35–0.98)

0.044

Gender

0.793

Female

Male

Age(years)

0.227

Diabetes

No

Yes

1.00

1.39(0.75–2.58)

0.284

History of HB

No

Yes

1.00

1.07(0.64–1.81)

0.774

Liver Cirrhosis

No

Yes

1.00

0.91(0.58–2.02)

0.790

AFP(µg/L)

<400

≥ 400

1.00

0.97(0.52–1.80)

0.937

PIVKA-II(mAU/ml)

<40

≥ 40

1.00

1.61(0.85-3.05)

0.141

Ascites

No

Yes

1.00

2.59(1.51–4.46)

<0.001

1.00

2.00(1.01–3.96)

0.046

MELD

Low risk

Medium risk

1.00

4.65(3.01–7.19)

<0.001

1.00

2.47(1.23–4.93)

0.010

ALBI

Level 1

Level 2

1.00

1.39(0.80–2.41)

0.239

Child-pugh Stage

A

B

1.00

3.30(1.88–5.80)

<0.001

1.00

1.82(0.77–4.32)

0.17

ECOG performance status

0

1

2

1.00

1.38(0.71–2.67)

1.04(0.50–2.18)

0.339

0.905

BCLC Stage

A

B

C

1.00

2.63(1.19–5.84)

3.16(1.45–6.87)

0.016

0.003

1.00

2.30(1.05–5.02)

3.35(1.56–7.19)

0.036

0.001

Largest nodule size (cm)

≥ 5

<5

1.00

1.33(0.72–2.66)

0.325

Tumor multiplicity

Unifocal

Multifocal

1.00

1.25(0.74–2.12)

0.388

Vascular Invasion

No

Yes

1.00

1.78(1.04–3.07)

0.034

1.00

1.48(0.88–2.47)

0.13

Lymphatic Metastasis

No

Yes

1.00

1.42(0.84–2.41)

0.182

Extrahepatic metastasis

No

Yes

1.00

1.63(0.93–2.84)

0.082